Subscribe

AptaBio Therapeutics Inc. (293780.KQ)

KRW4,340.00 +250.00 (+6.11%)
KR KOE Healthcare Drug Manufacturers - Specialty & Generic
Address Tower 504, 13 16954
Yongin-si, KR
CEO Jin Lee Soo
Website aptabio.com
IPO 2019-06-12
ISIN KR7293780003

Explore sections of this company profile

Description

AptaBio Therapeutics Inc. specializes in the discovery and advancement of innovative therapeutic agents. Its core activities encompass developing specific inhibitors for the NOX enzyme family and crafting aptamer-based anti-cancer medicines. Additionally, the company supplies a range of transfection reagents, including Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent, which are utilized for introducing DNA or RNA into eukaryotic cells. Key drug candidates in its pipeline include PX-115, designed to address diabetic nephropathy; APX-1004, intended for diabetic retinopathy; and APX-311, targeting non-alcoholic steatohepatitis (NASH). Founded in 2009, AptaBio Therapeutics is headquartered in Yongin-Si, South Korea.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
KRW4,340.00 +250.00 (+6.11%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
132.3K
Beta
0.80
Float Shares
19.53M
Free Float %
72.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-4.62% -13.31% -29.28% -19.71% -28.52% -36.07% -30.27% -44.89% -85.17% -85.17% -85.17%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
4,340.00
Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
4.04
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +10.0% ★ Q1'26: +150.2% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +54.4% ★ Q1'26: -149.6% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -589.8% Q1'26: -835.8% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    -419.3% Q1'26: +47.4% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    -44.9% Q1'26: +4.9% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +16.7% Q1'26: +0.1% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    -0.29× Q1'26: 2.57× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.71) × ERP
WACC = 97% × Ke + 3% × Kd (47.9%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 4,340.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C- 1/5 1/5 1/5 1/5 3/5 1/5 2/5
2026-05-28 C- 1/5 1/5 1/5 1/5 3/5 1/5 2/5
2026-05-27 C- 1/5 1/5 1/5 1/5 3/5 1/5 2/5
2026-05-26 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-19 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-18 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-15 C- 1/5 1/5 1/5 1/5 3/5 1/5 2/5
2026-05-14 C- 1/5 1/5 1/5 1/5 3/5 1/5 2/5
2026-05-13 C- 1/5 1/5 1/5 1/5 3/5 1/5 2/5
2026-05-12 C- 1/5 1/5 1/5 1/5 3/5 1/5 2/5
2026-05-11 C- 1/5 1/5 1/5 1/5 3/5 1/5 2/5
2026-05-08 C- 1/5 1/5 1/5 1/5 3/5 1/5 2/5
2026-05-07 C- 1/5 1/5 1/5 1/5 3/5 1/5 2/5
2026-05-06 C- 1/5 1/5 1/5 1/5 3/5 1/5 2/5
2026-05-04 C- 1/5 1/5 1/5 1/5 3/5 1/5 2/5
2026-04-30 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-29 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-28 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-27 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-24 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-23 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-22 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-21 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-20 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-17 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5
2026-04-16 C- 1/5 1/5 1/5 1/5 2/5 1/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-8.81B
OE per share TTM
-342.18
Owner's Yield
-5.47%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
390.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-4.84M
Shares Outstanding
26.88M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Hwan Moon Sung President & CSO — —
Jin Lee Soo Chief Executive Officer — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic